The FDA has expanded the approved indication for nogapendekin alfa inbakicept-pmln, commercially known as Anktiva, to treat adults with high-grade papillary-only non-muscle invasive bladder cancer (NMIBC) that has failed to respond to standard Bacillus Calmette-Guérin (BCG) treatments. Used in tandem with BCG, this innovative combination therapy effectively provides an essential alternative to radical bladder removal surgeries. Clinical trial indicators demonstrate that over 80% of patients remained completely cancer-free a year into the trial, introducing an invaluable milestone for advanced urological care.
About the Author
